A Protective Effect of Pirfenidone in Lung Fibroblast–Endothelial Cell Network via Inhibition of Rho-Kinase Activity
Open Access
- 12 August 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2259
Abstract
Pulmonary fibrosis is a life-threatening disease that has been attributed to several causes. Specifically, vascular injury is thought to be involved in the pathogenesis of fibrosis. The effects of the antifibrotic drug pirfenidone on angiogenesis have not been fully elucidated. This study aimed to investigate the effects of pirfenidone in human lung fibroblast–endothelial cell co-culture network formation and to analyze the underlying molecular mechanisms. Human lung fibroblasts were co-cultured with human umbilical vein endothelial cells to establish a co-culture network cell sheet. The influence of pirfenidone was evaluated for protective effect on the endothelial network in cell sheets stimulated with transforming growth factor β (TGF-β). Results indicated that TGF-β disrupted the network formation. Pirfenidone and Y27632 (Rho-associated coiled-coil containing protein kinase [Rho-kinase or ROCK] inhibitor) protected against the TGF-β–induced endothelial network disruption. TGF-β activated Rho-kinase signaling in cells composing the co-culture cell sheet, whereas pirfenidone and Y27632 inhibited these effects. In conclusion, TGF-β–induced Rho-kinase activation and disrupted endothelial network formation. Pirfenidone suppressed TGF-β–induced Rho-kinase activity in cell sheets, thereby enabling vascular endothelial cells networks to be preserved in the cell sheets. These findings suggest that pirfenidone has potential vascular network–preserving effect via inhibiting Rho-kinase activity in vascular injury, which is a precursor to pulmonary fibrosis.Keywords
Funding Information
- Japan Society for the Promotion of Science (19K17644)
This publication has 57 references indexed in Scilit:
- Hypoxia and Hypoxia Signaling in Tissue Repair and Fibrosis2012
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Gradual Increase of High Mobility Group Protein B1 in the Lungs after the Onset of Acute Exacerbation of Idiopathic Pulmonary FibrosisPulmonary Medicine, 2011
- Alveolar Macrophage Dysregulation in Hermansky-Pudlak Syndrome Type 1American Journal of Respiratory and Critical Care Medicine, 2009
- Lysophosphatidic Acid Induces αvβ6 Integrin-Mediated TGF-β Activation via the LPA2 Receptor and the Small G Protein GαqThe American Journal of Pathology, 2009
- Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosisEuropean Journal of Pharmacology, 2008
- Spatiotemporal dynamics of RhoA activity in migrating cellsNature, 2006
- RhoA and Rho-kinase dependent and independent signals mediate TGF-β-induced pulmonary endothelial cytoskeletal reorganization and permeabilityAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2005
- Corticosteroids for idiopathic pulmonary fibrosisCochrane Database of Systematic Reviews, 2003
- Role of RhoA and Rho Kinase in Lysophosphatidic Acid–Induced Endothelial Barrier DysfunctionArteriosclerosis, Thrombosis, and Vascular Biology, 2000